Roivant Sciences has agreed to go public through a merger with a blank-check firm backed by former KKR & Co Inc dealmaker Jim Momtazee, in a deal that values the Swiss biotech company at $7.3 billion.
The deal with Montes Archimedes Acquisition Corp, a special purpose acquisition company (SPAC), is expected to deliver up to $611 million of gross proceeds to fund discovery and development programs, the companies said on Monday.
That includes up to $411 million currently held in the SPAC’s trust account and $200 million from new and existing investors including Fidelity Management and SoftBank Group Corp unit SB Management.
Read more/Source: Reuters
Can't stop reading? This and all news articles are property of their creators, many are not owned or provided by Private Equity Insider. As an event organizer and community platform, we curate content from reliable sources for your suggested reading, and advise you to read the full articles from the referenced authors and sources.